The trial is designed to assess the time-to-relief in patients suffering from severe pain.
The research will build on previous findings that could enhance the performance of other cancer therapeutics such as checkpoint inhibitors, which activate the immune system to destroy cancer cells.
Researchers are striving to develop a full-profile, non-psychoactive cannabis extract product to help meet unmet medical needs.
Securing testing results from an ISO 17025 accredited laboratory is the best way for cannabis producers to ensure that they are producing high-quality, safe products.
Recent findings contrast with pre-existing data that shows the drug is linked to an increased chance of suicidal behaviour in the general population.
While cannabis flower characterized the market in the early years, cannabis extracts have become increasingly popular and eclipsed cannabis flower sales this year.
Anandia plans to accelerate their current breeding efforts to create the next-generation of cannabis plants and, expand their testing capabilities.
Medical marijuana has picked up considerable momentum after a U.S. FDA advisory panel unanimously recommended approval of GW Pharmaceuticals' epilepsy medication, Epidolex.
MMJ is seeking to scientifically assess and prove the effectiveness of their THC/CBD compounds treating and preventing symptoms associated with multiple sclerosis.